Trial reportScientific reports2023
An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.
Trial report in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis.Journal of nephrology · 2025Pooled it
- Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis.International urology and nephrology · 2026Article
- Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies.Cureus · 2026Review
- Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence.Kidney international reports · 2026Article
- Generic Controlled-Release Budesonide in IgA Nephropathy - A Single Center Retrospective Study.Kidney international reports · 2026Article
- Enteric Budesonide Treatment in IgA Nephropathy.Kidney international reports · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective.Clinical kidney journal · 2025Article
- Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.Heliyon · 2025Review
- Histological reappraisal of IgA nephropathy: the role of glomerular pattern of injury and mesangial complement deposition.BMC nephrology · 2024Observational
- Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study, ISRCTN47722295, date of registration 14/02/2020). Patients were treated with Budesonide at a dose of 9 mg/day for 12 months, subsequently tapered to 3 mg/day for another 12 months. The primary endpoints were change of eGFR and proteinuria at 12, 24 and 36 months. The study cohort had a mean eGFR and 24-h proteinuria of 59 ± 24 ml/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.